UBS Initiates Coverage On Ensysce Biosciences with Buy Rating, Announces Price Target of $2

Benzinga · 2d ago
UBS analyst Ashwani Verma initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Buy rating and announces Price Target of $2.